公开(公告)号：US09890121B2

公开(公告)日：2018-02-13

申请号：US14767054

申请日：2014-02-12

Applicant: Cipla Limited

Inventor： Rajendra Narayanrao Kankan ,  Srinivas Laxminarayan Pathi ,  Venugopalarao Chinimilli

IPC: C07D211/70 ,  C07D211/82 ,  C07D213/06 ,  C07D213/58 ,  C07D213/42

CPC classification number: C07D213/58 ,  C07D213/42

Abstract: The present invention relates to a process for the preparation of Compound (A): wherein the process comprises contacting atazanavir base (Compound (II)) with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compound (A), and to Compound (A) devoid of mesityl oxide impurity. Mesityl oxide has the following formula:

公开(公告)号：US10301282B2

公开(公告)日：2019-05-28

申请号：US15559325

申请日：2016-03-21

Applicant: Cipla Limited

Inventor： Dharmaraj Ramachandra Rao ,  Geena Malhotra ,  Srinivas Laxminarayan Pathi ,  Venugopalarao Chinimilli ,  Manish Gopaldas Gangrade

IPC: C07D401/14

Abstract: The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.